Indications for STRIVERDI RESPIMAT:
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
Limitations of Use:
Not indicated to treat acute deteriorations of COPD or for treatment of asthma.
Take at same time each day. 2 inh once daily; max 2 inh/24hrs.
STRIVERDI RESPIMAT Contraindications:
Use of LABA without inhaled corticosteroid (ICS) in asthma.
STRIVERDI RESPIMAT Warnings/Precautions:
LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in acute deteriorating COPD. Not for relief of acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Discontinue if paradoxical bronchospasm or hypersensitivity reactions occur; use alternative therapy. Cardiovascular disease (esp. coronary insufficiency, arrhythmias, hypertrophic obstructive cardiomyopathy, hypertension). Convulsive disorders. Thyrotoxicosis. Prolongation of the QT interval. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Risk of hypokalemia or hyperglycemia. Severe hepatic impairment. Pregnancy. Labor & delivery. Nursing mothers.
STRIVERDI RESPIMAT Classification:
Long-acting beta-2 agonist (LABA).
STRIVERDI RESPIMAT Interactions:
Caution with concomitant other adrenergic drugs. Concomitant xanthine derivatives, steroids, K+-depleting diuretics may potentiate hypokalemia. Extreme caution with MAOIs, tricyclics, or drugs known to prolong QTc interval. Antagonized by β-blockers; if needed, consider cardioselective agents. Potentiated by strong CYP450 and P-gp inhibitors (eg, ketoconazole).
Nasopharyngitis, URTI, bronchitis, UTI, cough, dizziness, rash, diarrhea, back pain, arthralgia.
Generic Drug Availability:
Inhaler (w. cartridge)—4g (60 inh)